Background Patients undergoing high-risk percutaneous coronary intervention (PCI) are at risk for hemodynamic compromise. In addition to an intraaortic balloon pump, TandemHeart and the Impella device may also be used…
Background The aims of our study were to evaluate the complications and long-term outcomes of PCI with implantations of long biolimus A9-eluting stents in proximal anterior descending artery (LAD). Methods…
Background A lot of drug-eluting stents (DESs) are implanted every year around the world, but the problem of in-stent restenosis remains in interventional cardiology. Nowadays, the optimal approach to paclitaxel-eluting…
Background Current practice guidelines still recommend coronary artery bypass graft (CABG) as the standard treatment in patients with left main coronary disease (LMCD). The purpose of our study is to…
Background The percutaneous treatment of aorto-ostial stenoses is challenging. There is a paucity of data regarding the success of accurately positioning stents in the aorto-ostial location. Methods We retrospectively reviewed…
Background The Endeavor TM stent (Medtronic Corp., USA) represents a second-generation drug-eluting stent (DES). The combination of a nickel–chromium–cobalt alloy, a phosphorylcholine polymer and zotarolimus makes this stent somewhat unique….
Background Women with coronary artery disease are at higher risk for adverse outcomes than men after coronary intervention. The SPIRIT IV clinical trial, a prospective, multicenter, randomized controlled trial, compared…
Background There is currently a paucity of data regarding the clinical outcome of the everolimus-eluting stent (EES) in unselected patients with the whole spectrum of obstructive coronary artery disease as…
Background Patients with lesions located in small vessels are at increased risk of adverse outcomes after PCI. Improved safety and efficacy have been previously demonstrated with XIENCE V stents in…
Background Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVG) is associated with poor outcomes. Improvement in pharmacology and technologies might translate to better outcomes after SVG PCI. However, there…
